Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists.

Spread the love

Declaration of competing interest MS – Research funding and consulting fees from Greenwich Biosciences, Inc. PM – Research funding from Greenwich Biosciences, Inc. Consultant, advisory speaker, and advisor for Greenwich Biosciences, Eisai, Supernus, Sunovion, Mallinkrodt, and Liva Nova. HL – Employed by Canopy Health Innovations. JPS – Research funding: NIH, NSF, Shor Foundation for Epilepsy Research, Department of Defense, UCB Pharma Inc., NeuroPace Inc., Greenwich Biosciences Inc., Biogen Inc., Xenon Pharmaceuticals, Serina Therapeutics Inc., and Eisai, Inc. Consulting/Advisory Boards: SAGE Therapeutics Inc., Greenwich Biosciences Inc., NeuroPace, Inc., Upsher-Smith Laboratories, Inc., Medical Association of the State of AL, Serina Therapeutics Inc., LivaNova Inc., UCB Pharma Inc., Lundbeck, SK LifeSciences, and Elite Medical Experts LLC. Editorial board member for Epilepsy & Behavior, Journal of Epileptology (associate editor), Epilepsy & Behavior Reports (associate editor), Journal of Medical Science, Epilepsy Currents (contributing editor), and Folia Medica Copernicana. Eric Segal – Consulting/Advisory: Zogenix, Neurelis, Greenwich Biosciences, Encoded, Aquestive, Celgene. Speaker: Eisai, Novartis, Greenwich Biosciences, Nutria, Lundbeck. LC and DB declare no conflicts of interest.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Ce site utilise Akismet pour réduire les indésirables. En savoir plus sur comment les données de vos commentaires sont utilisées.

error: Content is protected !!
%d blogueurs aiment cette page :